• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·UK·Financial Services·MAV4.L
Share

Maven Income & Growth VCT 4 Ord Stocks

£ 50Last Updated 18.06.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

£ 112.09M

£ 50
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Maven Income and Growth VCT 4 PLC operates as a venture capital trust, directing its capital primarily towards companies in mature and later growth phases. The fund's mandate includes investing in well-established small and medium-sized enterprises (SMEs) across diverse sectors, as well as businesses publicly traded on the AIM or ISDX exchanges. All its investments are made exclusively within the United Kingdom. Annually, the trust limits its capital injection into any single portfolio company to £1 million ($1.2 million). A key objective is to secure a majority ownership position in the businesses it backs, and it also actively pursues co-investment arrangements.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.07.2026 22:30

Oncology drugs helped boost AstraZeneca's profits by 21%. Will the company expand its portfolio?

27.07.2026 22:13

Plata has appointed the former U.S. ambassador to Russia to its board of directors

27.07.2026 21:56

Bank of America announced the temporary closure of its positions in Kazakh government bonds

27.07.2026 21:42

Nvidia has invested in Ilya Sutskever's AI startup. Why is it doing this?

27.07.2026 21:17

Shares of U.S. chipmakers plummeted following the IPO of a Chinese competitor

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026